Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis”: [Annals of Oncology 33 (2022) 321-329]
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2023-07, Vol.34 (7), p.630-630 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 630 |
|---|---|
| container_issue | 7 |
| container_start_page | 630 |
| container_title | Annals of oncology |
| container_volume | 34 |
| creator | Curigliano, G. Mueller, V. Borges, V. Hamilton, E. Hurvitz, S. Loi, S. Murthy, R. Okines, A. Paplomata, E. Cameron, D. Carey, L.A. Gelmon, K. Hortobagyi, G.N. Krop, I. Loibl, S. Pegram, M. Slamon, D. Ramos, J. Feng, W. Winer, E. |
| description | |
| doi_str_mv | 10.1016/j.annonc.2022.12.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2758116980</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753422047731</els_id><sourcerecordid>2758116980</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3235-b9d71712c5c5f976ce82f489436c8e2509d00cbdb9cdd3e64cc534a7d65f063f3</originalsourceid><addsrcrecordid>eNp9kstu1DAUhgPi0qHwBgh5OV1k8CXOpQukMhRaaVAlVFYIWY59Ulwldmo7g4ZVHwRerk-Co2lZsrJ9znf-43PJstcErwgm5dvrlbTWWbWimNIVoSuM-eNsQXjZ5DUuyJNsgRvK8oqz4iB7EcI1xrhsaPM8O2AlLwta88WjZ2vnvbkCq6cBRYfubn9fTkpGY02LtuDDFNDYSwWtQ1Jr0DMUvQxx-jUNskXSaqTkCMpE2RoLqHMejUkAbAzop4k_0OghepAxBZ-dfqEf0AAxCSRGoTY5QkwKVoHf47PifHFTTG5p7AMfIKDlrLDenH9-f3SMOmNlj1z6pux7FCa_NdtkkMm6Cybc3f45Rt9ObHoG5Dp0YZXr3dUOMYaWc9eOEKMkZ7T5_jJ72iUKXt2fh9nXj6eX67N8c_HpfH2yyRWjjOdtoytSEaq44l1TlQpq2hV1U7BS1UA5bjTGqtVto7RmUBZKpe7LSpe8wyXr2GG23OuO3t1MEKIYTFDQ99KCm4KgFa8JKZsaJ7TYo8q7EDx0YvRmkH4nCBbzBohrsd8AMdciCBVpA1LYm_sMUzuA_hf0MPIEvNsDkOrcGvAiqDQsBdp4UFFoZ_6f4S-we8e6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2758116980</pqid></control><display><type>article</type><title>Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis”: [Annals of Oncology 33 (2022) 321-329]</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Curigliano, G. ; Mueller, V. ; Borges, V. ; Hamilton, E. ; Hurvitz, S. ; Loi, S. ; Murthy, R. ; Okines, A. ; Paplomata, E. ; Cameron, D. ; Carey, L.A. ; Gelmon, K. ; Hortobagyi, G.N. ; Krop, I. ; Loibl, S. ; Pegram, M. ; Slamon, D. ; Ramos, J. ; Feng, W. ; Winer, E.</creator><creatorcontrib>Curigliano, G. ; Mueller, V. ; Borges, V. ; Hamilton, E. ; Hurvitz, S. ; Loi, S. ; Murthy, R. ; Okines, A. ; Paplomata, E. ; Cameron, D. ; Carey, L.A. ; Gelmon, K. ; Hortobagyi, G.N. ; Krop, I. ; Loibl, S. ; Pegram, M. ; Slamon, D. ; Ramos, J. ; Feng, W. ; Winer, E.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1016/j.annonc.2022.12.005</identifier><identifier>PMID: 36564285</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Annals of oncology, 2023-07, Vol.34 (7), p.630-630</ispartof><rights>2022 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3235-b9d71712c5c5f976ce82f489436c8e2509d00cbdb9cdd3e64cc534a7d65f063f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36564285$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Curigliano, G.</creatorcontrib><creatorcontrib>Mueller, V.</creatorcontrib><creatorcontrib>Borges, V.</creatorcontrib><creatorcontrib>Hamilton, E.</creatorcontrib><creatorcontrib>Hurvitz, S.</creatorcontrib><creatorcontrib>Loi, S.</creatorcontrib><creatorcontrib>Murthy, R.</creatorcontrib><creatorcontrib>Okines, A.</creatorcontrib><creatorcontrib>Paplomata, E.</creatorcontrib><creatorcontrib>Cameron, D.</creatorcontrib><creatorcontrib>Carey, L.A.</creatorcontrib><creatorcontrib>Gelmon, K.</creatorcontrib><creatorcontrib>Hortobagyi, G.N.</creatorcontrib><creatorcontrib>Krop, I.</creatorcontrib><creatorcontrib>Loibl, S.</creatorcontrib><creatorcontrib>Pegram, M.</creatorcontrib><creatorcontrib>Slamon, D.</creatorcontrib><creatorcontrib>Ramos, J.</creatorcontrib><creatorcontrib>Feng, W.</creatorcontrib><creatorcontrib>Winer, E.</creatorcontrib><title>Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis”: [Annals of Oncology 33 (2022) 321-329]</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kstu1DAUhgPi0qHwBgh5OV1k8CXOpQukMhRaaVAlVFYIWY59Ulwldmo7g4ZVHwRerk-Co2lZsrJ9znf-43PJstcErwgm5dvrlbTWWbWimNIVoSuM-eNsQXjZ5DUuyJNsgRvK8oqz4iB7EcI1xrhsaPM8O2AlLwta88WjZ2vnvbkCq6cBRYfubn9fTkpGY02LtuDDFNDYSwWtQ1Jr0DMUvQxx-jUNskXSaqTkCMpE2RoLqHMejUkAbAzop4k_0OghepAxBZ-dfqEf0AAxCSRGoTY5QkwKVoHf47PifHFTTG5p7AMfIKDlrLDenH9-f3SMOmNlj1z6pux7FCa_NdtkkMm6Cybc3f45Rt9ObHoG5Dp0YZXr3dUOMYaWc9eOEKMkZ7T5_jJ72iUKXt2fh9nXj6eX67N8c_HpfH2yyRWjjOdtoytSEaq44l1TlQpq2hV1U7BS1UA5bjTGqtVto7RmUBZKpe7LSpe8wyXr2GG23OuO3t1MEKIYTFDQ99KCm4KgFa8JKZsaJ7TYo8q7EDx0YvRmkH4nCBbzBohrsd8AMdciCBVpA1LYm_sMUzuA_hf0MPIEvNsDkOrcGvAiqDQsBdp4UFFoZ_6f4S-we8e6</recordid><startdate>202307</startdate><enddate>202307</enddate><creator>Curigliano, G.</creator><creator>Mueller, V.</creator><creator>Borges, V.</creator><creator>Hamilton, E.</creator><creator>Hurvitz, S.</creator><creator>Loi, S.</creator><creator>Murthy, R.</creator><creator>Okines, A.</creator><creator>Paplomata, E.</creator><creator>Cameron, D.</creator><creator>Carey, L.A.</creator><creator>Gelmon, K.</creator><creator>Hortobagyi, G.N.</creator><creator>Krop, I.</creator><creator>Loibl, S.</creator><creator>Pegram, M.</creator><creator>Slamon, D.</creator><creator>Ramos, J.</creator><creator>Feng, W.</creator><creator>Winer, E.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202307</creationdate><title>Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis”: [Annals of Oncology 33 (2022) 321-329]</title><author>Curigliano, G. ; Mueller, V. ; Borges, V. ; Hamilton, E. ; Hurvitz, S. ; Loi, S. ; Murthy, R. ; Okines, A. ; Paplomata, E. ; Cameron, D. ; Carey, L.A. ; Gelmon, K. ; Hortobagyi, G.N. ; Krop, I. ; Loibl, S. ; Pegram, M. ; Slamon, D. ; Ramos, J. ; Feng, W. ; Winer, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3235-b9d71712c5c5f976ce82f489436c8e2509d00cbdb9cdd3e64cc534a7d65f063f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Curigliano, G.</creatorcontrib><creatorcontrib>Mueller, V.</creatorcontrib><creatorcontrib>Borges, V.</creatorcontrib><creatorcontrib>Hamilton, E.</creatorcontrib><creatorcontrib>Hurvitz, S.</creatorcontrib><creatorcontrib>Loi, S.</creatorcontrib><creatorcontrib>Murthy, R.</creatorcontrib><creatorcontrib>Okines, A.</creatorcontrib><creatorcontrib>Paplomata, E.</creatorcontrib><creatorcontrib>Cameron, D.</creatorcontrib><creatorcontrib>Carey, L.A.</creatorcontrib><creatorcontrib>Gelmon, K.</creatorcontrib><creatorcontrib>Hortobagyi, G.N.</creatorcontrib><creatorcontrib>Krop, I.</creatorcontrib><creatorcontrib>Loibl, S.</creatorcontrib><creatorcontrib>Pegram, M.</creatorcontrib><creatorcontrib>Slamon, D.</creatorcontrib><creatorcontrib>Ramos, J.</creatorcontrib><creatorcontrib>Feng, W.</creatorcontrib><creatorcontrib>Winer, E.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Curigliano, G.</au><au>Mueller, V.</au><au>Borges, V.</au><au>Hamilton, E.</au><au>Hurvitz, S.</au><au>Loi, S.</au><au>Murthy, R.</au><au>Okines, A.</au><au>Paplomata, E.</au><au>Cameron, D.</au><au>Carey, L.A.</au><au>Gelmon, K.</au><au>Hortobagyi, G.N.</au><au>Krop, I.</au><au>Loibl, S.</au><au>Pegram, M.</au><au>Slamon, D.</au><au>Ramos, J.</au><au>Feng, W.</au><au>Winer, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis”: [Annals of Oncology 33 (2022) 321-329]</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2023-07</date><risdate>2023</risdate><volume>34</volume><issue>7</issue><spage>630</spage><epage>630</epage><pages>630-630</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36564285</pmid><doi>10.1016/j.annonc.2022.12.005</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2023-07, Vol.34 (7), p.630-630 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2758116980 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis”: [Annals of Oncology 33 (2022) 321-329] |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T14%3A09%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Corrigendum%20to%20%E2%80%9CTucatinib%20versus%20placebo%20added%20to%20trastuzumab%20and%20capecitabine%20for%20patients%20with%20pretreated%20HER2D%20metastatic%20breast%20cancer%20with%20and%20without%20brain%20metastases%20(HER2CLIMB):%20final%20overall%20survival%20analysis%E2%80%9D:%20%5BAnnals%20of%20Oncology%2033%20(2022)%20321-329%5D&rft.jtitle=Annals%20of%20oncology&rft.au=Curigliano,%20G.&rft.date=2023-07&rft.volume=34&rft.issue=7&rft.spage=630&rft.epage=630&rft.pages=630-630&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1016/j.annonc.2022.12.005&rft_dat=%3Cproquest_cross%3E2758116980%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2758116980&rft_id=info:pmid/36564285&rft_els_id=S0923753422047731&rfr_iscdi=true |